Who is sponsoring NCT03581513?

NCT03581513 is sponsored by Harbin Medical University.

What drugs are being tested in NCT03581513?

Interventions in NCT03581513: Deferred or Immediate Stent Implantation.

What condition does NCT03581513 study?

NCT03581513 studies Microcirculatory Perfusion, ST Elevation Myocardial Infarction.

Is NCT03581513 still recruiting?

NCT03581513 is currently terminated. Last updated 1 July 2022.

Last reviewed 2022-07-01 · How we verify

NCT03581513: SALVAGE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Deferred or Immediate Stent Implantation Based on Microvascular Function in STEMI

Terminated NA Last updated 1 July 2022

What this trial tests

NA trial testing Deferred or Immediate Stent Implantation in Microcirculatory Perfusion in 629 participants. Terminated before completion.

Timeline

20 December 2017

Primary endpoint
31 August 2021

31 August 2021

Quick facts

Lead sponsor	Harbin Medical University
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	629
Start date	20 December 2017
Primary completion	31 August 2021
Estimated completion	31 August 2021
Sites	8 locations across China

Drugs / interventions tested

Deferred or Immediate Stent Implantation

Conditions studied

Microcirculatory Perfusion — all drugs for Microcirculatory Perfusion →
ST Elevation Myocardial Infarction — all drugs for ST Elevation Myocardial Infarction →

Sponsor

Harbin Medical University

Who can join

Adults 18 to 80, any sex, with Microcirculatory Perfusion or ST Elevation Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Timely percutaneous coronary intervention (PCI) with stenting implantation is the current standard treatment for patients with ST-segment elevation myocardial infarction (STEMI). However, stenting in thrombus-laden artery is associated with higher risk of embolization and no-or slow-reflow, leading to larger infarct size and poor prognosis. The SALVAGE study is a prospective, multicenter, randomized, controlled study aimed to optimize the therapeutic strategies (deferred vs. immediate stenting) to protect microvascular function and eventually improve clinical outcomes at 12-months in STEMI.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Coronary Microcirculation: The Next Frontier in the Management of STEMI.
Milasinovic D, Nedeljkovic O, Maksimovic R, Sobic-Saranovic D, et al · · 2023 · cited 16× · PMID 36836137 · DOI 10.3390/jcm12041602
Optical Coherence Tomography Assessment of Coronary Lesions Associated With Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction.
Feng X, Xu Y, Zeng M, Qin Y, et al · · 2023 · cited 9× · PMID 37407487 · DOI 10.1253/circj.cj-23-0200
Novel Applications for Invasive and Non-invasive Tools in the Era of Contemporary Percutaneous Coronary Revascularisation.
Alkhalil M. · · 2022 · cited 3× · PMID 33530910 · DOI 10.2174/1573403x17666210202102549
Intracoronary Diagnostics in Patients with Acute Coronary Syndrome.
Sun Q, Liu M, Zeng M, Jia H. · · 2023 · cited 1× · PMID 39077404 · DOI 10.31083/j.rcm2402045

Verify or expand the search:

Other Harbin Medical University trials

Trials by the same sponsor.

NCT07471815 — Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mecha · Phase 2 · active not recruiting
NCT07187674 — The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonr · NA · not yet recruiting
NCT07161791 — Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer · Phase 1, PHASE2 · not yet recruiting
NCT07033624 — Cardiovascular Risk Early Screening and Warning in Harbin : A Prospective Cohort Study · not yet recruiting
NCT06947148 — The Impact of Comprehensive Post Hospital Management Based on DHI on Cardiac Function in Patients With HF · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03581513 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Harbin Medical University
Last refreshed: 1 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03581513.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing